As previously reportedly. Craig-Hallum analyst Matthew Hewitt initiated coverage of Dyadic International (DYAI) with a Buy rating and $5 price target The firm likes the overlap of the multiple near-term catalysts from the commercialization of their portfolio. Moreover, Craig-Hallum sees the possibility of substantial gains from partners advancing Dyadic’s proprietary platforms through their clinical research. With shares currently trading at a multiple of 2.7-times EV to FY26 sales, a discount to peers, the firm thinks the current valuation offers an attractive entry point for investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI:
- Dyadic International initiated with a Buy at Craig-Hallum
- Dyadic International’s Earnings Call Highlights Growth and Challenges
- Dyadic Applied BioSolutions: Strategic Shift and Financial Growth
- Dyadic International Closes $5.3 Million Stock Offering
- Dyadic International prices 6.05M shares at 95c in underwritten public offering